Margaret A. Shipp

45.3k total citations · 14 hit papers
210 papers, 24.6k citations indexed

About

Margaret A. Shipp is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Margaret A. Shipp has authored 210 papers receiving a total of 24.6k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Pathology and Forensic Medicine, 118 papers in Oncology and 61 papers in Molecular Biology. Recurrent topics in Margaret A. Shipp's work include Lymphoma Diagnosis and Treatment (136 papers), CAR-T cell therapy research (51 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Margaret A. Shipp is often cited by papers focused on Lymphoma Diagnosis and Treatment (136 papers), CAR-T cell therapy research (51 papers) and Cancer Immunotherapy and Biomarkers (43 papers). Margaret A. Shipp collaborates with scholars based in United States, Italy and France. Margaret A. Shipp's co-authors include Scott J. Rodig, Bjoern Chapuy, Donna Neuberg, Philippe Armand, Jeffery L. Kutok, Przemysław Juszczyński, Stefano Monti, Gordon J. Freeman, Jing Ouyang and Kunihiko Takeyama and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Margaret A. Shipp

204 papers receiving 24.2k citations

Hit Papers

Report of an Internationa... 1999 2026 2008 2017 1999 2014 2002 2010 2017 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
    1999 2.8k citations Margaret A. Shipp, Richard T. Hoppe et al. Journal of Clinical Oncology profile →
  2. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    2014 2.7k citations Stephen M. Ansell, Gordon J. Freeman et al. profile →
  3. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
    2002 1.8k citations Margaret A. Shipp, Jeffery L. Kutok et al. Nature Medicine profile →
  4. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
    2010 928 citations Michael R. Green, Stefano Monti et al. Blood profile →
  5. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
    2017 694 citations Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology profile →
  6. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
    2013 657 citations Benjamin J. Chen, Bjoern Chapuy et al. Clinical Cancer Research profile →
  7. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    2009 590 citations Margaret A. Shipp et al. Blood profile →
  8. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
    2016 555 citations Margaretha G.M. Roemer, Ranjana H. Advani et al. Journal of Clinical Oncology profile →
  9. Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
    2012 551 citations Michael R. Green, Scott J. Rodig et al. Clinical Cancer Research profile →
  10. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
    2013 550 citations Bjoern Chapuy, Stefano Monti et al. profile →
  11. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
    2016 477 citations Philippe Armand, Margaret A. Shipp et al. Journal of Clinical Oncology profile →
  12. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
  13. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
    2017 339 citations Margaretha G.M. Roemer, Bjoern Chapuy et al. Blood profile →
  14. The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
    2007 263 citations Przemysław Juszczyński, Jing Ouyang et al. Proceedings of the National Academy of Sciences profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Margaret A. Shipp 13.8k 12.8k 7.7k 6.2k 4.5k 210 24.6k
Andreas Rosenwald 7.6k 0.6× 10.6k 0.8× 5.6k 0.7× 6.1k 1.0× 6.1k 1.3× 421 20.3k
Michael Pfreundschuh 8.3k 0.6× 10.1k 0.8× 6.5k 0.9× 5.7k 0.9× 4.1k 0.9× 421 20.6k
Andrew D. Zelenetz 8.6k 0.6× 13.8k 1.1× 3.4k 0.4× 2.9k 0.5× 6.0k 1.3× 376 19.3k
Scott J. Rodig 18.7k 1.4× 8.2k 0.6× 10.9k 1.4× 10.5k 1.7× 3.9k 0.9× 347 33.8k
Louis M. Staudt 9.4k 0.7× 10.8k 0.8× 11.3k 1.5× 15.4k 2.5× 6.3k 1.4× 293 34.8k
Riccardo Dalla‐Favera 14.4k 1.0× 15.2k 1.2× 13.0k 1.7× 16.4k 2.7× 9.3k 2.1× 300 40.4k
Ahmet Doǧan 5.8k 0.4× 6.5k 0.5× 2.9k 0.4× 6.1k 1.0× 2.8k 0.6× 382 16.9k
John G. Gribben 8.4k 0.6× 8.8k 0.7× 10.9k 1.4× 5.0k 0.8× 9.2k 2.0× 481 24.1k
Geraldine S. Pinkus 4.6k 0.3× 5.2k 0.4× 3.3k 0.4× 4.5k 0.7× 3.7k 0.8× 207 18.1k
Axel Benner 6.4k 0.5× 5.4k 0.4× 4.2k 0.5× 9.7k 1.6× 7.5k 1.6× 398 24.1k

Countries citing papers authored by Margaret A. Shipp

Since Specialization
Citations

This map shows the geographic impact of Margaret A. Shipp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret A. Shipp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret A. Shipp more than expected).

Fields of papers citing papers by Margaret A. Shipp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret A. Shipp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret A. Shipp. The network helps show where Margaret A. Shipp may publish in the future.

Co-authorship network of co-authors of Margaret A. Shipp

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret A. Shipp. A scholar is included among the top collaborators of Margaret A. Shipp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret A. Shipp. Margaret A. Shipp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chapuy, Bjoern, Timothy R. Wood, Chip Stewart, et al.. (2024). DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma. Blood. 145(18). 2041–2055. 2 indexed citations
2.
Shipp, Margaret A.. (2023). LESSONS LEARNED FROM THE GENETIC HETEROGENEITY OF LYMPHOID MALIGNANCIES. Hematological Oncology. 41(S2). 30–30.
3.
Mandato, Elisa, Tianfang Ma, Vignesh Shanmugam, et al.. (2023). Cd70 Deficiency Impairs CD4 + and CD8 + T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas. Blood. 142(Supplement 1). 1624–1624. 1 indexed citations
4.
Wright, Kyle, Jason L. Weirather, Sizun Jiang, et al.. (2023). Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging. Blood Advances. 7(16). 4633–4646. 19 indexed citations
5.
Mandato, Elisa, Qingsheng Yan, Jing Ouyang, et al.. (2023). MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8. Blood. 142(14). 1219–1232. 3 indexed citations
6.
Armand, Philippe, Pier Luigi Zinzani, Hun Ju Lee, et al.. (2023). Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 142(10). 878–886. 39 indexed citations
7.
Cader, Fathima Zumla, Xihao Hu, Walter L. Goh, et al.. (2020). A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine. 26(9). 1468–1479. 88 indexed citations
8.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
9.
Cader, Fathima Zumla, Ron C.J. Schackmann, Xihao Hu, et al.. (2018). Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood. 132(8). 825–836. 111 indexed citations
10.
Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132. 694 indexed citations breakdown →
11.
Wu, Xinqi, Jingjing Li, Xiaoyun Liao, et al.. (2017). Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunology Research. 5(6). 446–454. 58 indexed citations
12.
Roemer, Margaretha G.M., Ranjana H. Advani, Robert Redd, et al.. (2016). Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research. 4(11). 910–916. 139 indexed citations
13.
Hao, Yansheng, Bjoern Chapuy, Stefano Monti, et al.. (2014). Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo. Clinical Cancer Research. 20(10). 2674–2683. 99 indexed citations
14.
Chen, Benjamin J., Bjoern Chapuy, Jing Ouyang, et al.. (2013). PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research. 19(13). 3462–3473. 657 indexed citations breakdown →
15.
Green, Michael R., Scott J. Rodig, Przemysław Juszczyński, et al.. (2012). Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. Clinical Cancer Research. 18(6). 1611–1618. 551 indexed citations breakdown →
16.
Laderach, Diego J., Lucas D. Gentilini, Diego O. Croci, et al.. (2012). A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. Cancer Research. 73(1). 86–96. 138 indexed citations
17.
Green, Michael R., Stefano Monti, Riccardo Dalla‐Favera, et al.. (2011). Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proceedings of the National Academy of Sciences. 108(7). 2873–2878. 42 indexed citations
18.
Juszczyński, Przemysław, Scott J. Rodig, Jing Ouyang, et al.. (2010). MLL -Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. Clinical Cancer Research. 16(7). 2122–2130. 28 indexed citations
19.
Parekh, Samir, José M. Polo, Rita Shaknovich, et al.. (2007). BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 110(6). 2067–2074. 105 indexed citations
20.
Gribben, John G., et al.. (2002). Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. Journal of Clinical Oncology. 20(5). 1288–1294. 276 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Rosenwald Breakdown of academic impact, for papers by Michael Pfreundschuh Breakdown of academic impact, for papers by Andrew D. Zelenetz Breakdown of academic impact, for papers by Scott J. Rodig Breakdown of academic impact, for papers by Louis M. Staudt Breakdown of academic impact, for papers by Riccardo Dalla‐Favera Breakdown of academic impact, for papers by Ahmet Doǧan Breakdown of academic impact, for papers by John G. Gribben Breakdown of academic impact, for papers by Geraldine S. Pinkus Breakdown of academic impact, for papers by Axel Benner
Rankless by CCL
2026